Biomarkers for prediction and diagnostics of preeclampsia

Preeclampsia (PE) is a life-threatening complication of pregnancy associated with a high rate of maternal and perinatal morbidity and/or mortality. This study was aimed at evaluation of total and fetal cell-free DNA (cftDNA and cffDNA) in maternal plasma to assess whether this could represent a reli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	O. V. Radkov, L. N. Korichkina, O. V. Sizova, Y. V. Volf, E. K. Paramonova
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2018
Materias:	preeclampsia fetal cell-free dna total cell-free dna Science Q
Acceso en línea:	https://doaj.org/article/5a1b9dc062e24b2d9a6afb14cd15383c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5a1b9dc062e24b2d9a6afb14cd15383c
record_format	dspace
spelling	oai:doaj.org-article:5a1b9dc062e24b2d9a6afb14cd15383c2021-11-23T06:14:40ZBiomarkers for prediction and diagnostics of preeclampsia2541-94202587-959610.29413/ABS.2018-3.2.3https://doaj.org/article/5a1b9dc062e24b2d9a6afb14cd15383c2018-04-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/553https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596Preeclampsia (PE) is a life-threatening complication of pregnancy associated with a high rate of maternal and perinatal morbidity and/or mortality. This study was aimed at evaluation of total and fetal cell-free DNA (cftDNA and cffDNA) in maternal plasma to assess whether this could represent a reliable predictive marker of early, late PE and whether intrauterine growth restriction (IUGR) as seen in PE is associated with levels of cell-free DNA. Diagnostic criteria for fetal growth retardation are calculated from the results of blood test results obtained in 26-36 weeks of gestation. We performed a PCR assay to compare the cftDNA and cffDNA concentration in maternal plasma among 3 groups of pregnant women. These included 119 women with overt PE (47 - early PE, 72 - late PE), 24 women at risk for the disease who developed PE (8 -early PE, 16 - late PE), and 30 controls. CffDNA quantification is a promising marker for early preeclampsia prediction. Cut-off value of 0,87 ng/ml for cffDNA (87.5 % sensitivity and 66,67 % specificity). Since the increase in cftDNA and cffDNA seems to be related to the presence IUGR in pregnancies which are complicated with early PE. Thus, it suggests that cftDNA and cffDNA could represent a potential biomarker of IUGR among individuals with early PE.O. V. RadkovL. N. KorichkinaO. V. SizovaY. V. VolfE. K. ParamonovaScientific Сentre for Family Health and Human Reproduction Problemsarticlepreeclampsiafetal cell-free dnatotal cell-free dnaScienceQRUActa Biomedica Scientifica, Vol 3, Iss 2, Pp 20-24 (2018)
institution	DOAJ
collection	DOAJ
language	RU
topic	preeclampsia fetal cell-free dna total cell-free dna Science Q
spellingShingle	preeclampsia fetal cell-free dna total cell-free dna Science Q O. V. Radkov L. N. Korichkina O. V. Sizova Y. V. Volf E. K. Paramonova Biomarkers for prediction and diagnostics of preeclampsia
description	Preeclampsia (PE) is a life-threatening complication of pregnancy associated with a high rate of maternal and perinatal morbidity and/or mortality. This study was aimed at evaluation of total and fetal cell-free DNA (cftDNA and cffDNA) in maternal plasma to assess whether this could represent a reliable predictive marker of early, late PE and whether intrauterine growth restriction (IUGR) as seen in PE is associated with levels of cell-free DNA. Diagnostic criteria for fetal growth retardation are calculated from the results of blood test results obtained in 26-36 weeks of gestation. We performed a PCR assay to compare the cftDNA and cffDNA concentration in maternal plasma among 3 groups of pregnant women. These included 119 women with overt PE (47 - early PE, 72 - late PE), 24 women at risk for the disease who developed PE (8 -early PE, 16 - late PE), and 30 controls. CffDNA quantification is a promising marker for early preeclampsia prediction. Cut-off value of 0,87 ng/ml for cffDNA (87.5 % sensitivity and 66,67 % specificity). Since the increase in cftDNA and cffDNA seems to be related to the presence IUGR in pregnancies which are complicated with early PE. Thus, it suggests that cftDNA and cffDNA could represent a potential biomarker of IUGR among individuals with early PE.
format	article
author	O. V. Radkov L. N. Korichkina O. V. Sizova Y. V. Volf E. K. Paramonova
author_facet	O. V. Radkov L. N. Korichkina O. V. Sizova Y. V. Volf E. K. Paramonova
author_sort	O. V. Radkov
title	Biomarkers for prediction and diagnostics of preeclampsia
title_short	Biomarkers for prediction and diagnostics of preeclampsia
title_full	Biomarkers for prediction and diagnostics of preeclampsia
title_fullStr	Biomarkers for prediction and diagnostics of preeclampsia
title_full_unstemmed	Biomarkers for prediction and diagnostics of preeclampsia
title_sort	biomarkers for prediction and diagnostics of preeclampsia
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2018
url	https://doaj.org/article/5a1b9dc062e24b2d9a6afb14cd15383c
work_keys_str_mv	AT ovradkov biomarkersforpredictionanddiagnosticsofpreeclampsia AT lnkorichkina biomarkersforpredictionanddiagnosticsofpreeclampsia AT ovsizova biomarkersforpredictionanddiagnosticsofpreeclampsia AT yvvolf biomarkersforpredictionanddiagnosticsofpreeclampsia AT ekparamonova biomarkersforpredictionanddiagnosticsofpreeclampsia
_version_	1718416945519263744

Biomarkers for prediction and diagnostics of preeclampsia

Ejemplares similares